Catalyst Pharmaceuticals (CPRX) Net Income towards Common Stockholders (2010 - 2026)

Catalyst Pharmaceuticals' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $63.7 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 12.33% year-over-year to $63.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231.0 million (up 17.04% YoY) and the FY2025 annual result came in at $224.0 million, up 36.66% from the prior year.
• Net Income towards Common Stockholders was $63.7 million for Q1 2026 at Catalyst Pharmaceuticals, up from $62.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $63.7 million in Q1 2026 and bottomed at -$30.8 million in Q3 2023.
• A 5-year average of $34.6 million and a median of $37.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders tumbled 235.24% — and 2024, when it soared 242.65%.
• Catalyst Pharmaceuticals' Net Income towards Common Stockholders stood at $25.5 million in 2022, then slumped by 33.1% to $17.0 million in 2023, then jumped by 228.28% to $55.9 million in 2024, then rose by 11.46% to $62.3 million in 2025, then rose by 2.22% to $63.7 million in 2026.
• Business Quant data shows CPRX's Net Income towards Common Stockholders at $63.7 million in Q1 2026, $62.3 million in Q4 2025, and $52.8 million in Q3 2025.